# Phase II Study of GTx024 in Women With Metastatic Breast Cancer

> **NCT01616758** · PHASE2 · TERMINATED · sponsor: **GTx** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** GTx-024 9mg

## Key facts

- **NCT ID:** NCT01616758
- **Lead sponsor:** GTx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2014-06
- **Final completion:** 2016-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01616758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01616758, "Phase II Study of GTx024 in Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01616758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*